HR+/HER2- breast cancer—or hormone receptor-positive, HER2-negative breast cancer—is the most common subtype of breast cancer. It makes up about 70% of all breast cancer cases. HR+/HER2- breast cancer ...

The U.S. Food and Drug Administration (FDA) has approved Inluriyo (imlunestrant) for the treatment of adults with estrogen ...

Triple-negative breast cancer does not respond to targeted breast cancer treatments, which limits treatment to primarily ...

When cancer progresses on endocrine therapy, the next step is likely either a biopsy to gather tissue for testing or a liquid ...

Breast cancer is a complex disease with many types. Understanding the specific type and classification of the breast cancer you have is crucial so that you can fully participate as an informed partner ...

Precision medicine and genomic assays are crucial in personalizing treatment for HER2-negative breast cancer, especially in premenopausal women with node-positive disease. The RxPONDER trial indicates ...

Eli Lilly and Company (NYSE: LLY) today announced results from the primary overall survival (OS) analysis of the Phase 3 ...

Endocrine therapy typically slows cell cycle progression by reducing cyclin D1, which partners with CDK4/6 to promote cell ...

Now four years into a first-in-class FDA approval for certain HR-positive, HER2-negative early breast cancers, Eli Lilly’s ...

Adding abemaciclib to endocrine therapy improved overall survival in patients with HR-positive, HER2-negative, node-positive, high-risk early breast cancer.

Learn about HER2+ breast cancer, its aggressive nature, and the latest treatments available in India. Explore the impact of ...